Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Kanwaljit Brar

Pediatrics New York, NY Medical Doctor

NPI 1306005723 CMS profile 13835

150 E 32Nd St Fl 2, New York, NY 10016

Open in the dashboard

General payments

$8,956

58 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$245,614 paid to institutions, not to them · program years 2020–2024

Through program year 2025, Kanwaljit Brar of New York, NY is reported in the CMS Open Payments database as having received $8,956 across 58 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $245,614 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $387 12
2024 General $263 10
2023 General $481 12
2022 General $7,413 20
2021 General $38 2
2020 General $374 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Kanwaljit Brar
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Kanwaljit Brar were reported at $387. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Kanwaljit Brar Pediatrics median Middle half National median
2019 $0 $86 $31–$183 $163
2020 $374 $49 $22–$110 $114
2021 $38 $68 $27–$158 $132
2022 $7,413 $77 $30–$173 $149
2023 $481 $88 $33–$190 $160
2024 $263 $94 $34–$206 $164
2025 $387 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. Incyte Corporation $7,185 14 payments
  2. Genzyme Corporation $546 12 payments
  3. kaleo, Inc. $361 16 payments
  4. Aimmune Therapeutics, Inc. $350 1 payment
  5. ARS Pharmaceuticals Operations, Inc. $142 7 payments
  6. AstraZeneca Pharmaceuticals LP $125 1 payment
  7. Sanofi-Aventis U.S. LLC $95 1 payment
  8. GlaxoSmithKline, LLC. $71 4 payments
  9. Grifols USA, LLC $49 1 payment
  10. BioCryst US Sales Co., LLC $31 1 payment

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Consulting Fee $5,227 1 payment
  2. Food and Beverage $1,692 49 payments
  3. Travel and Lodging $1,262 5 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $679 2 payments
  5. Education $95 1 payment
Products named General payments · program years 2020–2025
  1. DUPIXENT $849 17 payments
  2. PALFORZIA $350 1 payment
  3. AUVI-Q Allergy $255 11 payments
  4. NEFFY $142 7 payments
  5. FASENRA $125 1 payment
  6. AUVI-Q Allergy $107 5 payments
  7. NUCALA $71 4 payments
  8. OPZELURA $61 2 payments
  9. Xembify $49 1 payment
  10. WAYRILZ $31 1 payment
  11. Other $31 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

58 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record